The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: A model-based analysis for Spain

Vaccine

Volumn 25, Issue 39-40, 2007, Pages 6900-6910

  Aballéa, Samuel ^a   De Juanes, Jose Ramón ^b   Barbieri, Marco ^c   Martin, Monique ^a   Chancellor, Jeremy ^a   Oyagüez, Itziar ^d   Verwee, Bertrand ^e   Largeron, Nathalie ^e  

^a i3 Innovus   (United Kingdom)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d Sanofi Pasteur MSD   (Spain)

^e SANOFI PASTEUR   (France)

Author keywords

Cost effectiveness; Influenza; Spain

Indexed keywords

INFLUENZA VACCINE;

ADULT; ARTICLE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; HEALTH CARE POLICY; HUMAN; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SPAIN; VALIDATION PROCESS;

COST-BENEFIT ANALYSIS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; SPAIN; VACCINATION;

EID: 34548558829     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.07.033     Document Type: Article

References (46)

1. Zimmerman R.K. Lowering the age for routine influenza vaccination to 50 years: AAFP leads the nation in influenza vaccine policy. American Academy of Family Physicians. Am Fam Physician 60 7 (1999) 2061-2070
2. Committee on Issues and Priorities for New Vaccine Development IoMNAoS. In: Kathleen R., Stratton, Jane S., Durch, Robert S., and Lawrence (Eds). Vaccines for the 21st century: a tool for decisionmaking (2001), National Academy Press, Washington
3. Aballéa S., Chancellor J., Martin M., Wutzler P., Carrat F., Gasparini R., et al. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. Value Health 10 2 (2007) 98-116
4. Neuzil K.M., Reed G.W., Mitchel Jr. E.F., and Griffin M.R. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 281 10 (1999) 901-907
5. Irwin D.E., Weatherby L.B., Huang W.Y., Rosenberg D.M., Cook S.F., and Walker A.M. Impact of patient characteristics on the risk of influenza/ILI-related complications. BMC Health Serv Res 1 1 (2001) 8
6. Arrowood J.R., and Hayney M.S. Immunization recommendations for adults with cancer. Ann Pharmacother 36 7-8 (2002) 1219-1229
7. Nichol K.L., and Mendelman P. Influence of clinical case definitions with differing levels of sensitivity and specificity on estimates of the relative and absolute health benefits of influenza vaccination among healthy working adults and implications for economic analyses. Virus Res 103 1-2 (2004) 3-8
8. Classification Committee of WONCA. ICHPPC-2-defined: inclusion criteria for the use of the rubrics of the International Classification of Health Problems in Primary Care (1983), Oxford University Press Inc., New York 487 p.
9. Uphoff H., Cohen J.M., Fleming D., and Noone A. Harmonisation of national influenza surveillance morbidity data from EISS: a simple index. Euro Surveill 8 7 (2003) 156-164
10. Department of Health. Health Survey for England 1996. Accessed at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsStatistics/DH_4002768, June 2005.
11. Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. Cost-effectiveness in health and medicine (1996), Oxford University Press, New York
12. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database. Syst Rev 2001;4:CD001269.
13. Campbell D.S., and Rumley M.H. Cost-effectiveness of the influenza vaccine in a healthy, working-age population. J Occup Environ Med 39 5 (1997) 408-414
14. Bridges C.B., Thompson W.W., Meltzer M.I., Reeve G.R., Talamonti W.J., Cox N.J., et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 284 13 (2000) 1655-1663
15. Nichol K.L., Mendelman P.M., Mallon K.P., Jackson L.A., Gorse G.J., Belshe R.B., et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 282 2 (1999) 137-144
16. Gross P.A., Hermogenes A.W., Sacks H.S., Lau J., and Levandowski R.A. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 123 7 (1995) 518-527
17. Szucs T.D., and Muller D. Influenza vaccination coverage rates in five European countries-a population-based cross-sectional analysis of two consecutive influenza seasons. Vaccine 23 43 (2005) 5055-5063
18. Jimenez R., Larrauri A., Carrasco P., Esteban J., Gomez-Lopez L.I., and Gil A. Influenza coverages in Spain and vaccination-related factors in the subgroup aged 50-64 years. Vaccine 21 25-26 (2003) 3550-3555
19. Tacken M., Braspenning J., Spreeuwenberg P., van den Hoogen H., van Essen G., de Bakker D., et al. Patient characteristics determine differences in the influenza vaccination rate more so than practice features. Prev Med 35 4 (2002) 401-406
20. Public health and aging: influenza vaccination coverage among adults aged > or =50 years and pneumococcal vaccination coverage among adults aged > or =65 years-United States, 2002. MMWR Morb Mortal Wkly Rep 2003;52(41):987-92.
21. Instituto Nacional de Estadística. Enfermedades de declaración obligatoria: Series mensuales del Boletín Mensual de Estadística. Accessed at http://www.ine.es/inebase/menu3_soc_en.htm. April 2005.
22. Sentiweb. Le service du Réseau Sentinelles. Bilans Annuels. Accessed at http://www.sentiweb.fr. April 2005.
23. Meier C.R., Napalkov P.N., Wegmuller Y., Jefferson T., and Jick H. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 19 11 (2000) 834-842
24. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289 2 (2003) 179-186
25. Barker W.H., and Mullooly J.P. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 112 6 (1980) 798-811
26. Carrat F., Sahler C., Rogez S., Leruez-Ville M., Freymuth F., Le Gales C., et al. Influenza burden of illness: estimates from a national prospective survey of household contacts in France. Arch Intern Med 162 16 (2002) 1842-1848
27. Fryback D.G., Chinnis Jr. J.O., and Ulvila J.W. Bayesian cost-effectiveness analysis. An example using the GUSTO trial. Int J Technol Assess Health Care 17 1 (2001) 83-97
28. van Essen G.A., Palache A.M., Forleo E., and Fedson D.S. Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly developing countries. Vaccine 21 16 (2003) 1780-1785
29. Nichol K.L. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 21 16 (2003) 1769-1775
30. Colombo G.L., Nicosia V., Lesma A., Madera A., Caruggi M., and Serra G. A Cost-benefit analysis of anti-influenza vaccination in a company in Italy (Snamprogetti). Pharmacoecon Ital Res Art 3 2 (2001) 71-80
31. Harper S.A., Fukuda K., Uyeki T.M., Cox N.J., and Bridges C.B. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 53 RR-6 (2004) 1-40
32. Nichol K.L. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 161 5 (2001) 749-759
33. Lee P.Y., Matchar D.B., Clements D.A., Huber J., Hamilton J.D., and Peterson E.D. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med 137 4 (2002) 225-231
34. Turner D., Wailoo A., Nicholson K., Cooper N., Sutton A., and Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 7 35 (2003) 1-182
35. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2004;3:CD001269.
36. Hak E., Buskens E., van Essen G.A., de Bakker D.H., Grobbee D.E., Tacken M.A., et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study. Arch Intern Med 165 3 (2005) 274-280
37. Garcia de Codes Ilario A., Arrazola Martinez M.P., de Juanes Pardo J.R., Sanz Gallardo M.I., Jaén Herreros F., and Lago Lopez E. Influenza vaccination in healthcare workers, strategies to achieve compliance in a general hospital. Med Clin (Barc) 123 14 (2004) 532-534
38. Turner D.A., Wailoo A.J., Cooper N.J., Sutton A.J., Abrams K.R., and Nicholson K.G. The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine 24 7 (2006) 1035-1043
39. SOIKOS (Centre d'estudis en economia de la salud i de la política social). Base de datos del SOIKOS. 2004.
40. Vademecum Internacional. Especialidades Farmaceuticas y Biologicas. Accessed at http://www.vademecum.medicom.es, April 2005.
41. Consejo General de Colegios Oficiales de Farmaceuticos. Base de datos del medicamento y parafarmacia (2004). Accessed at http://www.portalfarma.com, April 2005.
42. Sistema Nacional de Salud. Explotación de bases del CMBD. Estadísticos de referencia estatal de los sistemas de agrupación de registros de pacientes (G.D.R.), 1999.
43. Paternoster A. Labour Costs Survey 2000. Statistics in Focus 2003; 18(Theme 3).
44. Cole J.A., Loughlin J.E., Ajene A.N., Rosenberg D.M., Cook S.E., and Walker A.M. The effect of zanamivir treatment on influenza complications: a retrospective cohort study. Clin Ther 24 11 (2002) 1824-1839
45. OECD. Labour Market Statistics. Accessed at http://www1.oecd.org/scripts/cde/members/lfsdataauthenticate.asp, April 2005.
46. De Juanes J.R., Cisterna R., Sanz J., Magaz S., and Badia X. Efficiency of influenza vaccination in the working population in Spain. Gac Sanit 20 2 (2006) 101-107